Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)
Safety and Efficacy of Sirolimus-eluting Biodegradable Abluminal Coating Stents in Patients With a High Risk of Ischemic Events: a Single-center, Prospective, Observational Trial (GENTLE Registry)
Sponsor: Genoss Co., Ltd.
A observational or N/A phase clinical study on Coronary Artery Disease and Drug-eluting Stent, this trial is completed. The trial is conducted by Genoss Co., Ltd. and has accumulated 7 data snapshots since 2022. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Completed
Status: Recruiting → Completed
-
Sep 2025 — Dec 2025 [monthly]
Recruiting
-
Sep 2024 — Sep 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Apr 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Oct 2022 — Apr 2024 [monthly]
Recruiting
-
Sep 2022 — Oct 2022 [monthly]
Recruiting
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genoss Co., Ltd.
- Severance Hospital
- Yonsei University
For direct contact, visit the study record on ClinicalTrials.gov .